US FDA accepts for priority review Sanofi & Regeneron’s Dupixent sBLA for the targeted treatment of bullous pemphigoid: Paris Wednesday, February 19, 2025, 12:00 Hrs [IST] The U ...

Retirement and spousal benefits are available to individuals aged 61 years and 9 months or older, who can start receiving ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Beacon Hill Roll Call records local senator’s votes on roll calls from the week of Feb. 10-14. There were no roll Calls in the House last week. $425 MILLION FOR ...

Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25. If approved, FILSPARI could be the first and only approv ...

In Honeywell International Inc. v. 3G Licensing, S.A., Appeal No. 23-1354, the Federal Circuit held that under the obviousness standard of 35 U.S.C.

Lack of federal support threatens millions of Americans with disabilities’ livelihoods.

Q4 2024 Earnings Call Transcript February 11, 2025 Ecolab Inc. reports earnings inline with expectations. Reported EPS is ...

Beacon Hill Roll Call records local representatives’ votes on roll calls from the week of Feb. 3-7, 2025. There were no roll ...